Metformin versus Insulin for the Treatment of Gestational Diabetes
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking. METHODS: We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score less than 7, or prematurity. The trial was designed to rule out a 33% increase (from 30% to 40%) in this composite outcome in infants of women treated with metformin as compared with those treated with insulin. Secondary outcomes included neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance, and acceptability of treatment. RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the primary composite outcome was 32.0% in the group assigned to metformin and 32.2% in the insulin group (relative risk, 0.99 [corrected]; 95% confidence interval, 0.80 [corrected] to 1.23 [corrected]). More women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again (76.6% vs. 27.2%, P<0.001). The rates of other secondary outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [73]
In the citing paper
“It was concluded that metformin alone, or with supplemental insulin, was not associated with increased perinatal complications.”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [112]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [89]
In the citing paper
“Glyburide is effective in controlling blood glucose in women with gestational diabetes”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Dabelea, D., Hanson, R. L., Lindsay, R. S., Pettitt, D. J., Imperatore, G., Gabir, M. M., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2208 · Cited by 1,277
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856
Gestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677
Silverman, B. L., Metzger, B. E., Cho, N. H., & Loeb, C. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.611 · Cited by 643
Hoffman, L., Nolan, C., Wilson, J. D., Oats, J. J. N., & Simmons, D. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140192.x · Cited by 570
An Increase in the Incidence of Gestational Diabetes Mellitus: Northern California, 1991–2000
Ferrara, A., Kahn, H. S., Quesenberry, C. P., Riley, C., & Hedderson, M. M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000113623.18286.20 · Cited by 452
Glueck, C. J., Phillips, H., Cameron, D., Sieve-Smith, L., & Wang, P. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01666-6 · Cited by 430
Research works printed but not linked: 3
- Coetzee EJ, 1980, S Afr Med J, 58, 795
- Coetzee EJ, 1984, S Afr Med J, 65, 635
- Gutzin SJ, 2003, Can J Clin Pharmacol, 10, 179
Cited by
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
“useful to treat gestational diabetes (273).”
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
“Recently, data accumulated from case control studies [144] or the Metformin in Gestational Diabetes Trial [145] suggested that women treated with metformin had less weight gain and improved neonatal outcomes compared with those treated with insulin.”
ResultPractice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
“Metformin is increasingly being used to treat gestational diabetes.([50-52]) Metformin is carried across the placenta by transporters([53]) and the concentrations in the fetus are only slightly lower than in the mother.”
BackgroundMetformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Influence of Maternal Obesity on the Long-Term Health of Offspring
Godfrey, K. M., Reynolds, R. M., Prescott, S. L., Nyirenda, M., Jaddoe, V. W. V., Eriksson, J. G., & Broekman, B. F. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30107-3 · Cited by 1,059
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Gestational diabetes mellitus: mechanisms, treatment, and complications
Johns, E. C., Denison, F. C., Norman, J. E., & Reynolds, R. M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.09.004 · Cited by 828
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
Gestational Diabetes Mellitus: Risks and Management during and after Pregnancy
Buchanan, T. A., Xiang, A. H., & Page, K. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.96 · Cited by 718
Pregnancy complications in women with polycystic ovary syndrome
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv029 · Cited by 691
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
“Additionally, metformin-treated women with gestational diabetes have increased rates of preterm birth (89).”
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 535
“Studies showed that children exposed to metformin may have a higher prevalence of obesity, BMI, abdominal fat volume, or blood pressure (33, 34).”
BackgroundGestational diabetes mellitus: an updated overview
Chiefari, E., Arcidiacono, B., Foti, D., & Brunetti, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0607-5 · Cited by 522
“Recently, results of a large randomized controlled trial demonstrated no significant increase in perinatal complications among women with GDM who were randomly treated with metformin, as compared with GDM women who were treated with insulin [73].”
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 470
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
Metformin versus placebo in obese pregnant women without diabetes mellitus
Syngelaki, A., Nicolaides, K. H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., Pastides, A., & Shehata, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509819 · Cited by 394
Thompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Self-citationMaternal metabolism and obesity: modifiable determinants of pregnancy outcome
Nelson, S. M., Matthews, P., & Poston, L. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp050 · Cited by 370
“, 2009), and outcomes are improved if it is combined with pharmacological therapy including metformin (Tuffnell et al., 2003; Crowther et al., 2005; Rowan et al., 2008).”
BackgroundSzmuilowicz, E. D., Josefson, J. L., & Metzger, B. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.001 · Cited by 364
Saraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
Feig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.038 · Cited by 344
“This finding was mainly demonstrated by the Metformin in Gestational diabetes (MiG) trial (366), where there was an increase in spontaneous preterm births rather than iatrogenic preterm births.”
ResultRegensteiner, J. G., Golden, S., Huebschmann, A. G., Barrett-Connor, E., Chang, A. Y., Chyun, D., Fox, C. S., Kim, C., Mehta, N., Reckelhoff, J. F., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000343 · Cited by 334
13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s013 · Cited by 332
“port the efficacy and short-term safety of metformin (30,31) and glyburide (32) for the treatment of GDM, both agents”
Gestational diabetes: A clinical update
Kampmann, U. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.1065 · Cited by 325
Practice Bulletin No. 180: gestational diabetes mellitus.
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002159 · Cited by 324
Gestational diabetes mellitus: results from a survey of country prevalence and practices
Jiwani, A., Marseille, E., Lohse, N., Damm, P., Hod, M., & Kahn, J. G. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.587921 · Cited by 316
“Various studies have found OADs to be effective in achieving glycemic control [28–30]; however, metformin crosses the placental barrier and additional data are needed to establish its long-term safety during pregnancy [29,31].”
BackgroundVanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Self-citationEndocrine Disorders in Pregnancy
Ramos, G. A., & Moore, T. R. (2012) · Avery's Diseases of the Newborn · doi:10.1016/b978-1-4377-0134-0.10009-5 · Cited by 267
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s014 · Cited by 265
“While individual RCTs support limited efficacy of metformin (41,42) and glyburide (43) in reducing glucose levels for the treatment of GDM, these agents are not recommended as firstline treatment for GDM because they are known to cross the placenta and data on safety for offspring is lacking (22).”
BackgroundBaz, B., Riveline, J.-P., & Gautier, J.-F. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0378 · Cited by 260
Chiswick, C., Reynolds, R. M., Denison, F., Drake, A. J., Forbes, S., Newby, D. E., Walker, B. R., Quenby, S., Wray, S., Weeks, A., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00219-3 · Cited by 260
Perioperative Glycemic Control: An Evidence-based Review
Lipshutz, A. K. M., Gropper, M. A., Warner, D. S., & Warner, M. A. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181948a80 · Cited by 259
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Obesity in Pregnancy: ACOG Practice Bulletin, Number 230
(2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004395 · Cited by 252
Hebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251
Coustan, D. R. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.203331 · Cited by 250
Practice Bulletin No 156: Obesity in Pregnancy
(2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000001211 · Cited by 248
Webber, J., Charlton, M., & Johns, N. (2015) · British Journal of Diabetes · doi:10.15277/bjdvd.2015.029 · Cited by 245
Alfadhli, E. M. (2015) · Saudi Medical Journal · doi:10.15537/smj.2015.4.10307 · Cited by 245
Catalano, P., & deMouzon, S. H. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.15 · Cited by 243
Mack, L. R., & Tomich, P. G. (2017) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2017.02.002 · Cited by 228
Farahvar, S., Walfisch, A., & Sheiner, E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1476135 · Cited by 237
“Although there is compelling evidence of the merits of prepregnancy BS, more recent studies have indicated that metformin may be useful for treating and preventing obstetrical complications in confirmed GDM patients [133,134].”
Background15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s015 · Cited by 232
Developmental origins of NAFLD: a womb with a clue
Wesolowski, S. R., Kasmi, K. C. E., Jonscher, K. R., & Friedman, J. E. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.160 · Cited by 232
Gestational Diabetes Mellitus—Recent Literature Review
Modzelewski, R., Stefanowicz-Rutkowska, M. M., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195736 · Cited by 223
Metformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222
“In this meta-analysis, the incidence of requiring additional insulin to achieve euglycemia was especially high in the study of Rowan [27] (46.”
BackgroundMethodResultInfluentialBrownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
Treatments for gestational diabetes
Alwan, N., Tuffnell, D. J., & West, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003395.pub2 · Cited by 214
Ijäs, H., Vääräsmäki, M., Morin-Papunen, L., Keravuo, R., Ebeling, T., Saarela, T., & Raudaskoski, T. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02763.x · Cited by 215
Pharmacokinetics of metformin during pregnancy
Eyal, S., Easterling, T. R., Carr, D., Umans, J. G., Miodovnik, M., Hankins, G. D. V., Clark, S. M., Risler, L., Wang, J., Kelly, E. J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031245 · Cited by 209
“Our findings suggest that higher metformin doses may be required in pregnant patients with insufficient glycemic control, although the impact of dosages higher than 2500 mg/day on the fetus requires further evaluation (Glueck et al., 2004; Rowan et al., 2008; Wensel, 2009).”
BackgroundCan a Low–Glycemic Index Diet Reduce the Need for Insulin in Gestational Diabetes Mellitus?
Moses, R. G., Barker, M., Winter, M., Petocz, P., & Brand-Miller, J. C. (2009) · Diabetes Care · doi:10.2337/dc09-0007 · Cited by 202
“formin (5) can be used, the overwhelming”
Niromanesh, S., Alavi, A., Sharbaf, F. R., Amjadi, N., Moosavi, S., & Akbari, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.031 · Cited by 203
“lower in the metformin group without significant difference between the groups in the 2 weeks before delivery [17].”
BackgroundResultInfluentialHanem, L. G. E., Stridsklev, S., Júlíusson, P. B., Salvesen, Ø., Roelants, M., Carlsen, S. M., Ødegård, R., & Vanky, E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02419 · Cited by 199
Gestational diabetes: risks, management, and treatment options
Kim, C. (2010) · International Journal of Women's Health · doi:10.2147/ijwh.s13333 · Cited by 192
Farrar, D., Tuffnell, D. J., West, J., & West, H. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005542.pub3 · Cited by 194
Gestational diabetes from A to Z
Mirghani Dirar, A., & Doupis, J. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i12.489 · Cited by 198
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects
Kamarudin, M. N. A., Sarker, M. M. R., Zhou, J.-R., & Parhar, I. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1495-2 · Cited by 191
“Metformin (1,1-dimethylbiguanide), a product of French lilac (Galega officinalis), is an oral biguanide and hypoglycemic agent that is prescribed to over 120 million patients with gestational diabetes [12, 13], T2DM [14, 15], non-alcoholic fatty liver disease [16, 17], premature puberty, [18] and polycystic ovarian sy…”
BackgroundAraujo Júnior, E., Peixoto, A. B., Zamarian, A. C. P., Elito Júnior, J., & Tonni, G. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.08.003 · Cited by 185
Randomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183
“7%).(5,14,17) These disparities are probably explained by differences in the populations studied”
BackgroundGestational diabetes: risk factors and recent advances in its genetics and treatment
Petry, C. J. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510001741 · Cited by 180
“Whilst there had been a number of previous reports of small studies (outlined in Cheung((150))), the use of metformin as a treatment (either as a sole agent or in conjunction with insulin injections) in recent years has been dominated by the Metformin in Gestational Studies study (MiG)((151)).”
ResultLandon, M. B., & Gabbe, S. G. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31823974e2 · Cited by 175
13. Management of Diabetes in Pregnancy
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s016 · Cited by 179
“While individual randomized controlled trials support the efficacy and short-term safety of metformin (26,27) and glyburide (28) for the treatment of GDM, both agents cross the placenta.”
Review: Role of metformin in the management of polycystic ovary syndrome
Lashen, H. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380215 · Cited by 173
“As for the safety profile, a study by Rowan and colleagues reported that the use of metformin in the treatment of GDM had no increased risk of perinatal complications [Rowan et al. 2008], which settled a previous controversy regarding metformin safety in pregnancy.”
BackgroundTertti, K., Ekblad, U., Koskinen, P., Vahlberg, T., & Rönnemaa, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12017 · Cited by 174
Metformin Compared With Glyburide in Gestational Diabetes: A Randomized Controlled Trial
Moore, L. E., Clokey, D., Rappaport, V. J., & Curet, L. B. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181c52132 · Cited by 177
PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery
Zhao, Y., Wang, W., Guo, S., Wang, Y., Miao, L., Xiong, Y., & Huang, L. (2016) · Nature Communications · doi:10.1038/ncomms11822 · Cited by 171
Butalia, S., Gutierrez, L., Lodha, A., Aitken, E., Zakariasen, A., & Donovan, L. (2017) · Diabetic Medicine · doi:10.1111/dme.13150 · Cited by 170
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 193
Treatments for gestational diabetes: A systematic review and meta-analysis
Farrar, D., Simmonds, M., Bryant, M., Sheldon, T. A., Tuffnell, D., Golder, S., & Lawlor, D. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015557 · Cited by 163
Nicholson, W., Bolen, S., Witkop, C. T., Neale, D., Wilson, L., & Bass, E. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318190a459 · Cited by 161
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158
Gestational Diabetes Mellitus and Preeclampsia: Correlation and Influencing Factors
Yang, Y., & Wu, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.831297 · Cited by 155
Pregnancy and diabetes scenario around the world: Africa
Coetzee, E. J. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2008.11.027 · Cited by 156
“(the Metformin in Gestational Diabetes (MiG) trial) [15].”
BackgroundSpaight, C., Gross, J., Horsch, A., & Puder, J. J. (2016) · Endocrine Development · doi:10.1159/000439413 · Cited by 148
(1993) · Diabetes Care · doi:10.2337/diacare.16.2.5 · Cited by 147
Dhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145
Gestational Diabetes: Pathogenesis and Consequences to Mother and Offspring
Kaaja, R., & Rönnemaa, T. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.194 · Cited by 144
“Oral hypoglycemic agents (glyburide and metformin) have been shown to be a possible alternative to insulin in the medical treatment of GDM [64-66].”
BackgroundBalani, J., Hyer, S. L., Rodin, D. A., & Shehata, H. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02780.x · Cited by 145
Cassina, M., Donà, M., Di Gianantonio, E., Litta, P., & Clementi, M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu022 · Cited by 143
“In addition, the rate of cases needing additional insulin to reach euglycemia was particularly high in one study (Rowan et al., 2008).”
BackgroundManagement of Diabetes in Pregnancy
Ballas, J., Moore, T. R., & Ramos, G. A. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0249-0 · Cited by 149
Guo, L., Ma, J., Tang, J., Hu, D., Zhang, W., & Zhao, X. Q. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9804708 · Cited by 157
“Moreover, severe neonatal hypoglycemia was lower compared to women on insulin alone [21, 22].”
BackgroundPrediction and prevention of the macrosomic fetus
Walsh, J., & McAuliffe, F. M. (2012) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.03.005 · Cited by 162
“Metformin in particular is increasingly used as a first-line medical treatment for gestational diabetes [73].”
BackgroundMurphy, H. R., Steel, S. A., Roland, J. M., Morris, D., Ball, V., Campbell, P. J., Temple, R. C., & on behalf of East Anglia Study Group for Improving Pregnancy Outcomes in Women with Diabetes (EASIPOD) (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03333.x · Cited by 134
The consequences of obesity and excess weight gain in pregnancy
Norman, J. E., & Reynolds, R. (2011) · Proceedings of the Nutrition Society · doi:10.1017/s0029665111003077 · Cited by 136
“insulin for the treatment of gestational diabetes study((48)).”
Background
Metadata
- Authors
- Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P.
- Affiliations
- Auckland City Hospital (NZ)
- Women's and Children's Hospital (AU)
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- Christchurch Hospital (NZ)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-08
- Volume
- 358
- Issue
- 19
- Pages
- 2003-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003621575
- Cited by
- 1,291
- References
- 33
- Citations by year
- 2026: 49 · 2025: 60 · 2024: 52 · 2023: 65 · 2022: 63 · 2021: 90 · 2020: 67 · 2019: 66 · 2018: 105 · 2017: 125 · 2016: 68 · 2015: 82 · 2014: 69 · 2013: 62 · 2012: 56
- FWCI
- 78.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, neonatal hypoglycemia, perinatal complications, maternal glycemic control, postpartum glucose tolerance, treatment acceptability, treatment preferences, neonatal respiratory distress, phototherapy
- MeSH terms
- Adult, Drug Therapy, Combination, Female, Gestational Age, Humans, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Jaundice, Neonatal, Metformin, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Diabetes, Gestational, Patient Satisfaction, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.